Key Highlights

● City Therapeutics launched its roadshow at $17 to $19 a share.

● Iambic Therapeutics set terms of $15 to $17 a share.

● DayOne Data Centers could raise up to $5 billion.

● Firmus withdrew an IPO sized at about A$7.1 billion.

The US market for initial public offerings did not see a new debut on Friday, but the pipeline kept filling. City Therapeutics, which plans to list on Nasdaq under the ticker CTY, launched its roadshow with an expected price range of $17 to $19 a share, according to market data. Iambic Therapeutics, which plans to list on Nasdaq as IAM, set terms of $15 to $17 a share.

A roadshow is the stretch, usually a week or two, in which a company and its bankers pitch the offering to institutional investors before the final price is set. Setting terms means the company has published a range, the step that usually comes shortly before pricing and the first day of trading.

Further back in the queue, DayOne Data Centers, which could raise up to $5 billion, and medical device maker Centinel Spine, which plans to list on the NYSE, have filed for offerings, according to market data.

Good timing for biotech

The two drug developers are approaching the market during a strong patch for health care stocks. Health care was one of the top-performing sectors in the S&P 500 on Friday and over the week. Vaccine and cancer-research names jumped after a report described a planned public-private initiative tied to the National Institutes of Health to fast-track cancer vaccine research, starting in December. Moderna (NASDAQ:MRNA) rose $28.00 to $225.00, and a biotech exchange-traded fund climbed during the session.

A rising sector can make investors more willing to back new issuers, though each offering ultimately depends on the company's own prospects and pricing.

A warning from Australia

Not every listing is going ahead. Firmus, an Nvidia-backed Australian data-centre company, withdrew its planned initial public offering of about A$7.1 billion, or roughly $4.95 billion, which would have valued it at about $30.6 billion, according to market data. The company cited market volatility and poor demand. Its board said "proceeding with the offer was not in the best interests of the company and its shareholders." Firmus is turning to private capital instead.

The withdrawal came during a rough patch for AI infrastructure stocks. On Thursday a report said that OpenAI's annualised revenue was about $50 billion at the end of September, well below an earlier figure, sending chip and data-centre names lower.

The SpaceX benchmark

The year's most closely watched listing is now trading actively. SpaceX (NASDAQ:SPCX), which priced its IPO at $150 a share, closed Friday at $162.57, up $2.00, after agreeing to buy nationwide wireless spectrum for about $8 billion and receiving a Barclays (NYSE:BCS) initiation at Overweight with a $254 price target.

The market backdrop

Conditions for new issues are mixed. Stocks are close to records, with the S&P 500 at 7,811.54 and the Cboe Volatility Index, Wall Street's fear gauge, down 0.57 to a calm 14.84. But US equity funds saw $5.11 billion of outflows in the week, according to market data, and the 10-year Treasury yield sits near a 24-year high after the Federal Reserve raised rates in September for the first time since 2023.

Debut Trading Will Show How Deep Biotech Demand Runs

The final pricing of the City Therapeutics and Iambic offerings, and how the shares trade on debut, will be the next test for biotech demand. On the macro calendar, September consumer price data arrive on Wednesday, October 14, followed by producer prices and retail sales on Thursday. Bank earnings begin on Tuesday, October 13, and the Fed meets October 27 to 28. Monday, October 12 brings a stock session but no bond trading, because of Columbus Day.